GEMS (Genesis Exploration of Molecular Space)
AI-powered platform for discovering novel small molecule therapeutics
Platform · OtherCompany source
Company profile
About Genesis Therapeutics
Genesis Therapeutics is a biotechnology company leveraging artificial intelligence and molecular simulation to discover and develop breakthrough medicines for patients with severe disorders. The company combines advanced machine learning techniques with molecular dynamics simulations to predict drug-target interactions and optimize drug candidates with unprecedented accuracy. Genesis Therapeutics focuses on challenging drug targets that have historically been difficult to address with traditional drug discovery methods. Their AI platform enables the design of highly selective small molecule therapeutics across multiple therapeutic areas. The company's approach integrates computational chemistry, structural biology, and medicinal chemistry to accelerate the drug discovery process and improve the probability of clinical success. Genesis Therapeutics is advancing a pipeline of novel drug candidates targeting serious diseases with significant unmet medical needs.
Company description Genesis Therapeutics official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Genesis Therapeutics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- severe disorders with high unmet medical need
Who it serves
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Translational Evaluation of In Vitro-to-In Vivo Extrapolation Techniques for Brain Penetration Using Open Flow Microperfusion and Microdialysis in Rats.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · Oct 16, 2026
Synthetic Approaches to the New Drugs Approved During 2024.Journal of medicinal chemistry · Jun 17, 2026
A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth.Cancer discovery · May 1, 2026
Application of modelling of cell monolayer permeation data to generate input parameters compatible with in vitro-in vivo translation of blood-brain-barrier disposition of drugs.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · May 1, 2026
Comparing massively-multitask regression algorithms for drug discovery.Journal of computer-aided molecular design · Feb 5, 2026
Alkyl sulfonyl fluorides as ambiphiles in the stereoselective palladium(II)-catalysed cyclopropanation of unactivated alkenes.Nature synthesis · Jan 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Genesis Therapeutics
Recent articles published on Genesis Therapeutics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.